Guardian Pharmacy Services, Inc. (GRDN) Operating Margin
- Operating margin · 12 months: Value 5.84%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 5.84% | Operating income / revenue. Period ending 2026-06-30. $85.44M ÷ $1.46B × 100 ≈ 5.84% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 85.44M USD | Operating Income (Loss) |
| Revenue | 1.46B USD | |
| Cost of products and services | 1.15B USD | Cost of Goods and Services Sold |
| Research and development | (m) | |
| Selling, general and administration | 231.14M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $85.44M | $1.46B | $1.15B | (m) | $231.14M | 5.84% |
| 2026-03-31 | $77.37M | $1.46B | $1.15B | (m) | $227.31M | 5.31% |
| 2025-12-31 | $72.70M | $1.45B | $1.16B | (m) | $220.02M | 5.02% |
| 2025-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $-62.92M | $1.23B | $984.04M | (m) | $307.29M | -5.12% |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.